Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
New Knowledge and Challenges in Breast Cancer
share announcement

New Knowledge and Challenges in Breast Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 8823

Special Issue Editor

Dr. Alba Di Leone

E-Mail Website
Guest Editor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Interests: breast cancer; breast pathology; breast reconstruction; breast surgery; cellulose
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The treatment of breast cancer presents many challenges in both diagnosis and treatment.

Radiomics and genomics offer opportunities to select patients for the most appropriate treatments and allow glimpses of new scenarios.

Increasingly, knowledge on the characteristics of tumor subtypes makes it possible to predict responses to treatments and to select the most appropriate courses of treatment.

Increasingly, targeted cancer treatments and new technical advances in surgical treatments allow us to glimpse an increasingly personalized future of breast cancer care that respects the integrity of the person. 

Let us prepare to change the nomenclature of breast cancers.

Dr. Alba Di Leone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • neoadjuvant chemotherapy
  • immunotherapy
  • triple-negative breast cancer
  • integrative medicine in breast cancer
  • radiomics
  • cancer vaccines
  • oncoplastic surgery
  • prepectoral reconstruction

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 4143 KiB  
Article
Primary Mucinous Cystadenocarcinoma of the Breast Intermixed with Pleomorphic Invasive Lobular Carcinoma: The First Report of This Rare Association
by Federica Vegni, Nicoletta D’Alessandris, Angela Santoro, Giuseppe Angelico, Giulia Scaglione, Angela Carlino, Damiano Arciuolo, Michele Valente, Stefania Sfregola, Maria Natale, Alejandro Martin Sanchez, Valeria Masciullo, Gian Franco Zannoni and Antonino Mulè
J. Pers. Med. 2023, 13(6), 948; https://doi.org/10.3390/jpm13060948 - 03 Jun 2023
Cited by 1 | Viewed by 1071
Abstract
Primary mucinous cystadenocarcinoma (MCA) is a rare breast carcinoma subtype showing overlapping histopathological features with mucinous cystadenocarcinoma of the ovary and pancreas. Current literature data suggest a favorable prognosis of breast MCAs despite its immunoprofile usually revealing lack of expression of estrogen receptor, [...] Read more.
Primary mucinous cystadenocarcinoma (MCA) is a rare breast carcinoma subtype showing overlapping histopathological features with mucinous cystadenocarcinoma of the ovary and pancreas. Current literature data suggest a favorable prognosis of breast MCAs despite its immunoprofile usually revealing lack of expression of estrogen receptor, progesterone receptor and HER-2 and high Ki67. As far as we know, only 36 cases have been reported in the literature to date. Its ambiguous morpho-phenotypic profile makes histological diagnosis very challenging. It must be distinguished from typical mucin-producing breast carcinomas and, above all, metastases from the same histotype in other sites (ovary, pancreas, appendix). Herein, we report the case of a primary breast MCA occurring in a 41-year-old female with peculiar histological features. Full article
(This article belongs to the Special Issue New Knowledge and Challenges in Breast Cancer)
►▼ Show Figures

Figure 1

8 pages, 424 KiB  
Article
Prepectoral vs. Submuscular Immediate Breast Reconstruction in Patients Undergoing Mastectomy after Neoadjuvant Chemotherapy: Our Early Experience
by Lorenzo Scardina, Alba Di Leone, Ersilia Biondi, Beatrice Carnassale, Alejandro Martin Sanchez, Sabatino D’Archi, Antonio Franco, Francesca Moschella, Stefano Magno, Daniela Terribile, Damiano Gentile, Alessandra Fabi, Anna D’Angelo, Liliana Barone Adesi, Giuseppe Visconti, Marzia Salgarello, Riccardo Masetti and Gianluca Franceschini
J. Pers. Med. 2022, 12(9), 1533; https://doi.org/10.3390/jpm12091533 - 19 Sep 2022
Cited by 5 | Viewed by 1279
Abstract
Background: Conservative mastectomy with immediate prosthetic breast reconstruction (IPBR) is an oncologically accepted technique that offers improved esthetic results and patient quality of life. Traditionally, implants have been placed in a submuscular (SM) plane beneath the pectoralis major muscle (PMM). Recently, prepectoral (PP) [...] Read more.
Background: Conservative mastectomy with immediate prosthetic breast reconstruction (IPBR) is an oncologically accepted technique that offers improved esthetic results and patient quality of life. Traditionally, implants have been placed in a submuscular (SM) plane beneath the pectoralis major muscle (PMM). Recently, prepectoral (PP) placement of the prosthesis has been increasingly used in order to avoid morbidities related to manipulation of the PMM. The aim of this study was to compare outcomes of SM vs. PP IPBR after conservative mastectomy in patients with histologically proven breast cancer treated with neoadjuvant chemotherapy (NAC). Methods: In this retrospective observational study, we analyzed two cohorts of patients that underwent mastectomy with IPBR after NAC in our institution from January 2018 to December 2021. Conservative mastectomy was performed in 146 of the 400 patients that underwent NAC during the study period. Patients were divided into two groups based on the positioning of implants: 56 SM versus 90 PP. Results: The two cohorts were similar for age (mean age 42 and 44 years in the SM and PP group respectively) and follow-up (33 and 20 months, respectively). Mean operative time was 56 min shorter in the PP group (300 and 244 min in the SM and PP group). No significant differences were observed in overall major complication rates. Implant loss was observed in 1.78% of patients (1/56) in the SM group and 1.11% of patients (1/90) in PP group. No differences were observed between the two groups in local or regional recurrence. Conclusions: Our preliminary experience, which represents one of the largest series of patients undergoing PP-IPBR after NAC at a single institution documented in the literature, seems to confirm that PP-IPBR after NAC is a safe, reliable and effective alternative to traditional SM-IPBR with excellent esthetic and oncological outcomes; it is easy to perform, reduces operative time and minimizes complications related to manipulation of PPM. However, this promising results need to be confirmed in prospective trials with longer follow-up. Full article
(This article belongs to the Special Issue New Knowledge and Challenges in Breast Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 1556 KiB  
Review
An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
by Farid Khallouki, Lhoussain Hajji, Somayya Saber, Toufik Bouddine, Mouad Edderkaoui, Mohammed Bourhia, Nora Mir, Adrian Lim, Adil El Midaoui, John P. Giesy, Mourad A. M. Aboul-Soud, Sandrine Silvente-Poirot and Marc Poirot
J. Pers. Med. 2023, 13(5), 754; https://doi.org/10.3390/jpm13050754 - 28 Apr 2023
Cited by 2 | Viewed by 3255
Abstract
Breast cancer (BC) is the most common female cancer in terms of incidence and mortality worldwide. Tamoxifen (Nolvadex) is a widely prescribed, oral anti-estrogen drug for the hormonal treatment of estrogen-receptor-positive BC, which represents 70% of all BC subtypes. This review assesses the [...] Read more.
Breast cancer (BC) is the most common female cancer in terms of incidence and mortality worldwide. Tamoxifen (Nolvadex) is a widely prescribed, oral anti-estrogen drug for the hormonal treatment of estrogen-receptor-positive BC, which represents 70% of all BC subtypes. This review assesses the current knowledge on the molecular pharmacology of tamoxifen in terms of its anticancer and chemo-preventive actions. Due to the importance of vitamin E compounds, which are widely taken as a supplementary dietary component, the review focuses only on the potential importance of vitamin E in BC chemo-prevention. The chemo-preventive and onco-protective effects of tamoxifen combined with the potential effects of vitamin E can alter the anticancer actions of tamoxifen. Therefore, methods involving an individually designed, nutritional intervention for patients with BC warrant further consideration. These data are of great importance for tamoxifen chemo-prevention strategies in future epidemiological studies. Full article
(This article belongs to the Special Issue New Knowledge and Challenges in Breast Cancer)
►▼ Show Figures

Figure 1

11 pages, 5556 KiB  
Review
Use of High-Frequency Transducers in Breast Sonography
by Antonio Corvino, Carlo Varelli, Fabio Catalano, Giulio Cocco, Andrea Delli Pizzi, Andrea Boccatonda, Fabio Corvino, Luigi Basile and Orlando Catalano
J. Pers. Med. 2022, 12(12), 1960; https://doi.org/10.3390/jpm12121960 - 27 Nov 2022
Cited by 12 | Viewed by 2632
Abstract
Sonography companies have recently developed high-frequency transducers (20–30 MHz) to image the skin and small joints. In this pictorial review, we present a number of settings where these probes can be usefully employed to scan the breast. These include skin abnormalities of the [...] Read more.
Sonography companies have recently developed high-frequency transducers (20–30 MHz) to image the skin and small joints. In this pictorial review, we present a number of settings where these probes can be usefully employed to scan the breast. These include skin abnormalities of the breast and axilla; nipple–areolar complex abnormalities; superficial breast parenchyma abnormalities; breast parenchyma abnormalities in subjects with implants; very small female breasts; peripheral areas in breasts of any size; pre-puberal breasts; male breasts; post-mastectomy chest wall; and intraoperative breast sonography. Comparatively, side-by-side images obtained with conventional breast frequencies and high frequencies are shown. Full article
(This article belongs to the Special Issue New Knowledge and Challenges in Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop